| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Editorial Board
|
|
|
|
|
1S1 |
p.
|
artikel
|
| 2 |
39MO Clinical evaluation of a low-coverage whole-genome test for homologous recombination deficiency detection in ovarian cancer
|
Boidot, R.
|
|
|
|
1S1 |
p.
|
artikel
|
| 3 |
74MO Clinical outcomes for pelvic node-positive vulvar carcinoma in the PET and IMRT era: Reassessing the stage IVb designation
|
Koerner, S.A.
|
|
|
|
1S1 |
p.
|
artikel
|
| 4 |
22MO Homologous recombination gene mutations in uterine serous cancer: A phenotype of the hereditary breast and ovarian cancer syndrome?
|
Ahsan, M.D.
|
|
|
|
1S1 |
p.
|
artikel
|
| 5 |
1MO Identification of RAD51 foci in cancer-associated circulating cells and their association with treatment outcomes, in patients with high-grade serous ovarian cancer (HGSOC)
|
Hall, M.
|
|
|
|
1S1 |
p.
|
artikel
|
| 6 |
36MO Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (OC): 5-year (y) progression-free survival (PFS) by molecular subgroup in the PAOLA-1/ENGOT-ov25 trial
|
Gonzalez Martin, A.J.
|
|
|
|
1S1 |
p.
|
artikel
|
| 7 |
37MO Niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: A post hoc analysis on efficacy by surgical timing and residual disease status in the phase III PRIME trial
|
Pan, L.
|
|
|
|
1S1 |
p.
|
artikel
|
| 8 |
40MO Targetable gene mutations in mucinous ovarian cancer
|
Levi, S.
|
|
|
|
1S1 |
p.
|
artikel
|
| 9 |
38MO Validation study of the ShallowHRDv2 assay for homologous recombination deficiency (HRD) detection in high-grade ovarian carcinomas (HGOC) in the first-line setting, from the phase III PAOLA-1/ENGOT-ov25 trial
|
Callens, C.
|
|
|
|
1S1 |
p.
|
artikel
|
| 10 |
34O ATR inhibitor alone (ceralasertib) or in combination with olaparib in gynaecological cancers with ARID1A loss or no loss: Results from the ENGOT/GYN1/NCRI ATARI trial
|
Banerjee, S.
|
|
|
|
1S1 |
p.
|
artikel
|
| 11 |
35O Overall survival of niraparib with individualized starting dose as maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer adjusted for subsequent PARPi use in placebo group: Results from an ad hoc interim analysis for the phase III NORA study
|
Wu, X.
|
|
|
|
1S1 |
p.
|
artikel
|
| 12 |
33O PRIMA/ENGOT-OV26/GOG-3012 study: Long-term conditional PFS
|
Gonzalez Martin, A.J.
|
|
|
|
1S1 |
p.
|
artikel
|
| 13 |
32O 5-year (y) overall survival (OS) with maintenance olaparib (ola) plus bevacizumab (bev) by clinical risk in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial
|
Lorusso, D.
|
|
|
|
1S1 |
p.
|
artikel
|
| 14 |
24P A phase II trial of docetaxel/cisplatin chemotherapy followed by pelvic radiation therapy in patients with high-risk endometrial carcinoma after staging surgery
|
Park, J-Y.
|
|
|
|
1S1 |
p.
|
artikel
|
| 15 |
50P Can we learn from failures? A systematic review and metanalysis of phase III trials in platinum resistant ovarian cancer
|
Martorana, F.
|
|
|
|
1S1 |
p.
|
artikel
|
| 16 |
13P Cervical cancer screening in a basic health unit in South of Brazil: Impact of the COVID-19 pandemic
|
Michelon, I.F.
|
|
|
|
1S1 |
p.
|
artikel
|
| 17 |
75P Clinical characteristics and desensitization protocol of chemotherapy-induced hypersensitivity reactions in patients with gynaecologic cancer
|
Kim, S-H.
|
|
|
|
1S1 |
p.
|
artikel
|
| 18 |
65P Clinical outcomes in ovarian clear cell carcinoma: A UK single centre experience
|
Peleg Hasson, S.
|
|
|
|
1S1 |
p.
|
artikel
|
| 19 |
14P Clinical outcomes of women who attend the Cameroon Baptist Convention Health Services (CBCHS) with cervical cancer
|
Calvin, N.
|
|
|
|
1S1 |
p.
|
artikel
|
| 20 |
28P Clinicopathologic characteristics and oncologic outcomes of mismatch repair-deficient/microsatellite instability-high endometrial cancer
|
Nam, S.
|
|
|
|
1S1 |
p.
|
artikel
|
| 21 |
11P Conization before radical hysterectomy in early cervical cancer: A Korean multi-center study
|
Lee, M.
|
|
|
|
1S1 |
p.
|
artikel
|
| 22 |
60P Deciphering CD8+ T-cell-related gene signatures in the tumor microenvironment to predict the immunotherapy response and prognosis of ovarian cancer patients
|
Zhu, Y.
|
|
|
|
1S1 |
p.
|
artikel
|
| 23 |
26P Demographics and survival outcomes in patients (pts) with advanced or recurrent (A/R) endometrial cancer (EC) in the English real-world (RW) setting
|
Ingles Russo Garces, A.H.
|
|
|
|
1S1 |
p.
|
artikel
|
| 24 |
62P Development of deep learning-based auto-segmentation algorithms to diagnose and indicate peritoneal carcinomatosis lesions of ovarian cancer
|
Kim, S.I.
|
|
|
|
1S1 |
p.
|
artikel
|
| 25 |
56P Differential response to DNA damaging agents of patients carrying the germline BRCA1 c.211 A>G pathogenic variant
|
Gomez-Randulfe Rodriguez, M.I.
|
|
|
|
1S1 |
p.
|
artikel
|
| 26 |
15P Efficacy and safety analysis of recombinant human endostatin (Endostar) combined with and chemoradiotherapy for locally advanced cervical cancer
|
Yu, J.
|
|
|
|
1S1 |
p.
|
artikel
|
| 27 |
80P Efficacy, FDA approval, innovativeness, clinical evidence, and price of breast, ovarian, endometrial, and cervical cancer drugs
|
Michaeli, J.C.
|
|
|
|
1S1 |
p.
|
artikel
|
| 28 |
42P Efficacy of maintenance with PARPi in advanced ovarian cancer according to the location of BRCA mutation
|
Marchetti, C.
|
|
|
|
1S1 |
p.
|
artikel
|
| 29 |
51P Efficacy of PARP inhibitors in patients with advanced high grade serous ovarian cancer according to BRCA domain mutations
|
Buonaiuto, R.
|
|
|
|
1S1 |
p.
|
artikel
|
| 30 |
78P Electronic tool for high grade adverse event (AE) reporting in gynecology (gyne) clinical trials (ClinT) at Princess Margaret Cancer Centre (PM)
|
Madariaga Urrutia, A.
|
|
|
|
1S1 |
p.
|
artikel
|
| 31 |
4P Evaluation of antitumor activity and immunogenic cell death (ICD) induction by MORAb-202 (farletuzumab ecteribulin) in human ovarian cancer (OV) models
|
Furuuchi, K.
|
|
|
|
1S1 |
p.
|
artikel
|
| 32 |
55P Evolution of genetic testing after ovarian cancer (OC) diagnosis
|
Lopes Bruno, A.T.
|
|
|
|
1S1 |
p.
|
artikel
|
| 33 |
59P Expression of CD47 a potent ‘don’t eat me signal' in ovarian cancer (OC): Correlation with other immune features and evolution under neoadjuvant chemotherapy (NACT), a GINEGEPS study
|
Chardin, L.
|
|
|
|
1S1 |
p.
|
artikel
|
| 34 |
54P Fallopian tube cancer and ovarian cancer: A real-world comparison of epidemiological patterns, clinical outcomes, and mutational landscape
|
Allam, A.R.
|
|
|
|
1S1 |
p.
|
artikel
|
| 35 |
49P First report on pan-immune-inflammation value as a new prognostic factor in ovarian cancer: A biomarker analysis of OVANORDEST-1 study
|
El Bairi, K.
|
|
|
|
1S1 |
p.
|
artikel
|
| 36 |
61P Fluorescent detection of epithelial cells in intraoperative flushes in ovarian cancer in the “liquid biochip” format
|
Kruglova, I.A.
|
|
|
|
1S1 |
p.
|
artikel
|
| 37 |
17P Impact of adjuvant chemoradiotherapy on survival outcome compared to other treatment modalities for cervical cancer stage IIIc
|
Ellaithy, A.
|
|
|
|
1S1 |
p.
|
artikel
|
| 38 |
16P Impact of preoperative versus postoperative radiotherapy and radical hysterectomy without systemic therapy on overall survival of early-stage cervical cancer patients
|
Abo El Haj, A.S.
|
|
|
|
1S1 |
p.
|
artikel
|
| 39 |
53P Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients
|
Farolfi, A.
|
|
|
|
1S1 |
p.
|
artikel
|
| 40 |
7P Integration of whole genome sequencing (WGS) into NHS pathways for high-grade ovarian cancer (HGOC): A single-centre prospective experience
|
Funingana, I.G.
|
|
|
|
1S1 |
p.
|
artikel
|
| 41 |
57P International ovarian tumor analysis (IOTA) simple ultrasound rules and risk of malignancy index in differentiating benign from malignant ovarian masses
|
Modi, S.S.
|
|
|
|
1S1 |
p.
|
artikel
|
| 42 |
46P Long-term residual chemotherapy-induced peripheral neuropathy (CIPN) and relationship with single nucleotide polymorphisms (SNPs) in ovarian cancer patients free of disease in the GINECO Vivrovaire study
|
Zenatri, M.
|
|
|
|
1S1 |
p.
|
artikel
|
| 43 |
64P Malignant Brenner tumor of the ovary: Impact of adjuvant chemotherapy, age, race, laterality and stage on survival outcome
|
Ellaithy, A.
|
|
|
|
1S1 |
p.
|
artikel
|
| 44 |
45P MITO39: Effiacy and tolerability of PLD-trabectedin in the treatment of relapsed ovarian cancer after maintenance therapy with PARP-i, a MITO observational case-control study
|
Turinetto, M.
|
|
|
|
1S1 |
p.
|
artikel
|
| 45 |
3P NaPi2b expression in high grade serous ovarian cancer: Results from combined data sets
|
Banerjee, S.
|
|
|
|
1S1 |
p.
|
artikel
|
| 46 |
19P Neoadjuvant chemotherapy followed by radical surgery vs chemoradiotherapy in patients with cervical cancer (stage IIB, FIGO 2018)
|
Abdujapparov, A.S.
|
|
|
|
1S1 |
p.
|
artikel
|
| 47 |
10P Neoadjuvant chemotherapy with bevacizumab for IIb stage cervical cancer: Is it time to rethink standard of care?
|
Djuraev, F.M.
|
|
|
|
1S1 |
p.
|
artikel
|
| 48 |
8P NXP800 versus cisplatin in ARID1a-mutated ovarian clear cell carcinoma xenograft models
|
Stewart, J.R.
|
|
|
|
1S1 |
p.
|
artikel
|
| 49 |
2P Outcomes of patients with gynecological tumors harboring HER2 defects: A single center study based on Gustave Roussy cancer center’s molecular program
|
Roussel-Simonin, C.
|
|
|
|
1S1 |
p.
|
artikel
|
| 50 |
29P Outcomes of patients with intermediate-high risk early stage endometrial cancer after surgery according to adjuvant treatment
|
Vecchi Leis, L.
|
|
|
|
1S1 |
p.
|
artikel
|
| 51 |
66P PD-L1 expression following neoadjuvant chemotherapy is upregulated and serves as a prognostic factor in patients with advanced high-grade serous ovarian carcinoma
|
Yano, M.
|
|
|
|
1S1 |
p.
|
artikel
|
| 52 |
41P Phase I analysis of ubamatamab (MUC16xCD3 bispecific antibody) in patients with recurrent ovarian cancer
|
Moore, K.N.
|
|
|
|
1S1 |
p.
|
artikel
|
| 53 |
5P Physiologically relevant treatment models to investigate epigenetic mechanisms driving platinum resistance in ovarian high grade serous carcinoma
|
Ergasti, R.
|
|
|
|
1S1 |
p.
|
artikel
|
| 54 |
47P Platinum rechallenge (PtRc) for high-grade epithelial ovarian cancer (HGEOC) patients (pts) considered not eligible for further platinum therapy (former platinum-resistant)
|
García-Illescas, D.
|
|
|
|
1S1 |
p.
|
artikel
|
| 55 |
23P Pre-treatment inflammatory indexes predict the clinical outcome of patients with endometrial cancer: A MITO24 study
|
Farolfi, A.
|
|
|
|
1S1 |
p.
|
artikel
|
| 56 |
68P Prognosis of ovarian cancer patients with the Mexican founder mutation (a BRCA1 long genomic rearrangement) compared with other BRCA1/2 mutations
|
Bahena, J.
|
|
|
|
1S1 |
p.
|
artikel
|
| 57 |
25P Prognostic classification of endometrial cancer according to transcriptomic-based immunophenotype
|
Quispe, E.M.
|
|
|
|
1S1 |
p.
|
artikel
|
| 58 |
70P Prognostic factors and outcome in ovarian adult granulosa-cell tumours: A retrospective real-world data
|
Spartacus, R.K.
|
|
|
|
1S1 |
p.
|
artikel
|
| 59 |
18P Prospective randomized comparison of quality of life in locally advanced cervical cancer treated with intracavitary or interstitial brachytherapy
|
Singh, A.
|
|
|
|
1S1 |
p.
|
artikel
|
| 60 |
20P Randomized comparison of four radiotherapy schedules in locally advanced cervical cancer: A prospective study
|
Choudhary, S.
|
|
|
|
1S1 |
p.
|
artikel
|
| 61 |
52P Real-world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group
|
Musacchio, L.
|
|
|
|
1S1 |
p.
|
artikel
|
| 62 |
44P Real-world overall survival in second-line maintenance niraparib monotherapy vs active surveillance in patients with recurrent ovarian cancer
|
Moore, K.N.
|
|
|
|
1S1 |
p.
|
artikel
|
| 63 |
63P Redefining the role of CA 19-9 as a prognostic marker in epithelial ovarian cancer
|
Kaur, E.J.
|
|
|
|
1S1 |
p.
|
artikel
|
| 64 |
69P Relationship between BRCA genotype by location and duration of response to iPARP treatment: Real-life data
|
Galvez Montosa, F.
|
|
|
|
1S1 |
p.
|
artikel
|
| 65 |
48P Response to chemotherapy following PARP inhibition in ovarian cancer (OC) patients at Mount Vernon Cancer Centre
|
Berner, A.M.
|
|
|
|
1S1 |
p.
|
artikel
|
| 66 |
67P Survival and reproductive outcomes of patients with malignant ovarian germ cell tumors, a retrospective analysis from a tertiary care center in India
|
Dey, S.
|
|
|
|
1S1 |
p.
|
artikel
|
| 67 |
71P Survival outcomes of patients with recurrent malignant ovarian germ cell tumors: A retrospective analysis from a tertiary cancer center
|
Anne, S.
|
|
|
|
1S1 |
p.
|
artikel
|
| 68 |
77P The impact of COVID-19 on gynecological cancer diagnoses in Greece
|
Fiste, O.
|
|
|
|
1S1 |
p.
|
artikel
|
| 69 |
58P The lymphocyte activation gene-3 (LAG-3) protein expression in tumor-infiltrating lymphocytes is associated with a poor prognosis of ovarian clear cell carcinoma
|
Zaitsu, S.
|
|
|
|
1S1 |
p.
|
artikel
|
| 70 |
79P The situation of gynecological cancer before and after COVID-19 pandemic years in Kosovo
|
Profka, B.
|
|
|
|
1S1 |
p.
|
artikel
|
| 71 |
9P The survival effect and prognostic factors of residual tumor confined to the uterus after radical radio-chemotherapy in cervical cancer
|
Dogan, B.
|
|
|
|
1S1 |
p.
|
artikel
|
| 72 |
43P Time to next treatment (TTNT) of first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC) patients (pts) in the CHAR1ZMA study
|
Coleman, R.L.
|
|
|
|
1S1 |
p.
|
artikel
|
| 73 |
12P Tisotumab vedotin in recurrent or metastatic cervical cancer
|
Bini, M.
|
|
|
|
1S1 |
p.
|
artikel
|
| 74 |
76P To do or not to do? Endometrial biopsy in younger women with abnormal uterine bleeding
|
Jaya-Bodestyne, S.L.
|
|
|
|
1S1 |
p.
|
artikel
|
| 75 |
27P Treatment outcomes and toxicity profiles in South Asian patients of high-risk endometrial cancer treated with PORTEC-3 trial regimen
|
Verma, P.
|
|
|
|
1S1 |
p.
|
artikel
|
| 76 |
6P Unveiling the impact of intra-tumor heterogeneity in treatment response to achieve personalized medicine for endometrial cancer patients
|
Villafranca Magdalena, B.
|
|
|
|
1S1 |
p.
|
artikel
|
| 77 |
31P Uterine cancer metastasis patterns and racial disparities: A SEER database population study 2010-2019
|
El-Sakka, A.A.
|
|
|
|
1S1 |
p.
|
artikel
|
| 78 |
30P Validation of MODEPLEX technology for the determination of POLE hotspot mutations in endometrial carcinoma samples
|
Dorca Duch, E.
|
|
|
|
1S1 |
p.
|
artikel
|
| 79 |
Table of Contents
|
|
|
|
|
1S1 |
p.
|
artikel
|
| 80 |
72TiP AVALON trial: Phase IIb study of maveropepimut-s and low-dose cyclophosphamide in subjects with platinum-resistant, epithelial ovarian cancer
|
Dorigo, O.
|
|
|
|
1S1 |
p.
|
artikel
|
| 81 |
21TiP Molecular alterations predictive of outcome in early staged cervical cancer: A translational investigation in the international validation study of sentinel node biopsy in early cervical cancer SENTICOL III
|
El Gani, M.
|
|
|
|
1S1 |
p.
|
artikel
|
| 82 |
73TiP Niraparib maintenance in first-line ovarian cancer: MITO 40, an observational real-life study
|
Di Napoli, M.
|
|
|
|
1S1 |
p.
|
artikel
|
Tijdschrift beschrijving